Pharmacokinetics and Safety of High-Dose and Extended-Interval Regimens of Levofloxacin in Human Immunodeficiency Virus-Infected Patients

Documenti analoghi

• Safety and Pharmacokinetics of Multiple 750-Milligram Doses of Intravenous Levofloxacin in Healthy Volunteers
  di: Chow, Andrew T., et al.
  Pubblicazione: (2001)
• Levofloxacin Population Pharmacokinetics and Creation of a Demographic Model for Prediction of Individual Drug Clearance in Patients with Serious Community-Acquired Infection
  di: Preston, Sandra L., et al.
  Pubblicazione: (1998)
• Double-Blind Evaluation of the Safety and Pharmacokinetics of Multiple Oral Once-Daily 750-Milligram and 1-Gram Doses of Levofloxacin in Healthy Volunteers
  di: Chien, Shu-Chean, et al.
  Pubblicazione: (1998)
• Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.
  di: Goodwin, S D, et al.
  Pubblicazione: (1994)
• Pharmacokinetic Evaluation of Oral Levofloxacin in Human Immunodeficiency Virus-Infected Subjects Receiving Concomitant Antiretroviral Therapy
  di: Villani, P., et al.
  Pubblicazione: (2001)